Recursion Pharmaceuticals has acquired full global rights to REV102, an investigational oral ENPP1 inhibitor being developed for hypophosphatasia (HPP), a rare genetic bone disease. The asset was previously under an exclusive license and collaboration agreement with gene therapy company Genascence.
According to the company, REV102 could become the first oral small molecule therapy designed to increase pyrophosphate levels, potentially addressing both pediatric and adult forms of HPP. Recursion said that existing treatment options, such as enzyme replacement therapies, may not fully meet patient needs, particularly in adults.
The company claims the acquisition aligns with its mission to apply technology-enabled drug discovery to rare diseases. Recursion plans to advance REV102 into clinical development, although specific timelines have not been disclosed.
Genascence, which originally developed REV102, will receive undisclosed financial terms under the agreement.
Hypophosphatasia is an inherited metabolic disorder characterized by defective bone mineralization and low levels of serum alkaline phosphatase. The company said that increasing extracellular pyrophosphate through ENPP1 inhibition may help restore bone health in affected patients.
The move expands Recursion’s pipeline of therapeutics aimed at addressing serious genetic disorders and highlights its strategic focus on leveraging computational tools to accelerate drug development.
